XML 55 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Pay Versus Performance
​
Pay Versus Performance Table
In accordance with the rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are providing the following information regarding the relationship between the “Compensation Actually Paid” to our CEO (also referred to as our “PEO”) and our other named executive officers (together, our “NEOs”) and certain financial performance measures for the Company. This information includes compensation information for our PEO and our NEOs, as well as information on our cumulative total shareholder return (“TSR”), the cumulative TSR of our peer group, our net income and our product revenues, net for the fiscal years listed below. For purposes of this section, “peer group” is defined as the Nasdaq Biotechnology Index, as further detailed in footnote 7 below.
Year
​ ​
Summary
Compensation
Table Total
for PEO
($)(1)
​ ​
Compensation
Actually Paid
to PEO
($)(2)(3)
​ ​
Average
Summary
Compensation
Table Total for
Non-PEO
Named
Executive
Officers
($)(4)
​ ​
Average
Compensation
Actually Paid
to Non-PEO
Named
Executive
Officers
($)(2)(5)
​ ​
Value of Initial Fixed $100
Investment Based on:
​ ​
Net Income
($ M)
​ ​
Total
Product
Revenues
($ M)(8)
​
​
Total
Shareholder
Return
($)(6)
​ ​
Peer Group
Total
Shareholder
Return
($)(7)
​
2024 ​ ​ ​ ​ 17,459,546 ​ ​ ​ ​ ​ 25,233,510 ​ ​ ​ ​ ​ 5,906,668 ​ ​ ​ ​ ​ 8,882,222 ​ ​ ​ ​ ​ 79.10 ​ ​ ​ ​ ​ 113.84 ​ ​ ​ ​ ​ 32.6 ​ ​ ​ ​ ​ 3,618.9 ​ ​
2023 ​ ​ ​ ​ 16,659,526 ​ ​ ​ ​ ​ 7,842,731 ​ ​ ​ ​ ​ 7,843,705 ​ ​ ​ ​ ​ 6,405,428 ​ ​ ​ ​ ​ 71.91 ​ ​ ​ ​ ​ 115.42 ​ ​ ​ ​ ​ 597.6 ​ ​ ​ ​ ​ 3,165.2 ​ ​
2022 ​ ​ ​ ​ 16,669,368 ​ ​ ​ ​ ​ 15,972,264 ​ ​ ​ ​ ​ 5,750,911 ​ ​ ​ ​ ​ 5,496,116 ​ ​ ​ ​ ​ 91.98 ​ ​ ​ ​ ​ 113.65 ​ ​ ​ ​ ​ 340.7 ​ ​ ​ ​ ​ 2,746.9 ​ ​
2021 ​ ​ ​ ​ 14,444,265 ​ ​ ​ ​ ​ 6,228,229 ​ ​ ​ ​ ​ 5,217,889 ​ ​ ​ ​ ​ 1,847,797 ​ ​ ​ ​ ​ 84.06 ​ ​ ​ ​ ​ 126.45 ​ ​ ​ ​ ​ 948.6 ​ ​ ​ ​ ​ 2,322.0 ​ ​
2020 ​ ​ ​ ​ 16,378,192 ​ ​ ​ ​ ​ 13,448,394 ​ ​ ​ ​ ​ 3,725,684 ​ ​ ​ ​ ​ 3,748,945 ​ ​ ​ ​ ​ 99.61 ​ ​ ​ ​ ​ 126.42 ​ ​ ​ ​ ​ (295.7) ​ ​ ​ ​ ​ 2,068.7 ​ ​
​
(1)
The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Hervé Hoppenot, our CEO.
​
(2)
The amounts shown for “Compensation Actually Paid “ (CAP) have been calculated in accordance with SEC rules and represent amounts reported in the Summary Compensation Table with certain adjustments as described in footnotes 3 and 5 below.
​
(3)
The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the “Compensation Actually Paid” for our PEO for each of the years presented:
​
Year
​ ​
Reported
Summary
Compensation
Table Total
for PEO
($)
​ ​
Reported
Value of
Equity Awards
($)
​ ​
CAP of
Equity
Vesting
during FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted prior to
the current FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted during
the current FY
($)
​ ​
Compensation
Actually Paid
to PEO
($)
​
2024 ​ ​ ​ ​ 17,459,546 ​ ​ ​ ​ ​ (13,858,712) ​ ​ ​ ​ ​ 304,971 ​ ​ ​ ​ ​ 3,302,113 ​ ​ ​ ​ ​ 18,025,592 ​ ​ ​ ​ ​ 25,233,510 ​ ​
2023 ​ ​ ​ ​ 16,659,526 ​ ​ ​ ​ ​ (13,759,707) ​ ​ ​ ​ ​ (2,202,340) ​ ​ ​ ​ ​ (1,080,176) ​ ​ ​ ​ ​ 8,225,428 ​ ​ ​ ​ ​ 7,842,731 ​ ​
2022 ​ ​ ​ ​ 16,669,368 ​ ​ ​ ​ ​ (13,783,149) ​ ​ ​ ​ ​ 1,005,994 ​ ​ ​ ​ ​ 2,981,288 ​ ​ ​ ​ ​ 9,098,763 ​ ​ ​ ​ ​ 15,972,264 ​ ​
2021 ​ ​ ​ ​ 14,444,265 ​ ​ ​ ​ ​ (12,088,636) ​ ​ ​ ​ ​ (606,066) ​ ​ ​ ​ ​ (1,960,844) ​ ​ ​ ​ ​ 6,439,510 ​ ​ ​ ​ ​ 6,228,229 ​ ​
2020 ​ ​ ​ ​ 16,378,192 ​ ​ ​ ​ ​ (13,832,247) ​ ​ ​ ​ ​ 2,043,085 ​ ​ ​ ​ ​ 127,113 ​ ​ ​ ​ ​ 8,732,251 ​ ​ ​ ​ ​ 13,448,394 ​ ​
​
(4)
Our non-PEO Named Executive Officers for 2024 comprises of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2023 are comprised of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2021 and 2022 were comprised of Ms. Stamoulis, Dr. Stein, Ms. Maria E. Pasquale, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2020 were comprised of Ms. Stamoulis, Dr. Stein, Dr. Flannelly, and Dr. Vijay Iyengar.
​
(5)
The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the Average Compensation Actually Paid for our non-PEO Named Executive Officers for each of the years presented:
​
Year
​ ​
Reported
Summary
Compensation
Table Total
for Non-PEO
NEOs
($)
​ ​
Reported
Value of
Equity Awards
($)
​ ​
CAP of
Equity Vesting
during FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted prior to
the current FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted during
the current FY
($)
​ ​
Compensation
Actually Paid
to Non-PEO
NEOs
($)
​
2024 ​ ​ ​ ​ 5,906,668 ​ ​ ​ ​ ​ (4,361,467) ​ ​ ​ ​ ​ 128,814 ​ ​ ​ ​ ​ 1,514,304 ​ ​ ​ ​ ​ 5,693,903 ​ ​ ​ ​ ​ 8,882,222 ​ ​
2023 ​ ​ ​ ​ 7,843,705 ​ ​ ​ ​ ​ (6,458,845) ​ ​ ​ ​ ​ (291,967) ​ ​ ​ ​ ​ 203,007 ​ ​ ​ ​ ​ 5,109,528 ​ ​ ​ ​ ​ 6,405,428 ​ ​
2022 ​ ​ ​ ​ 5,750,911 ​ ​ ​ ​ ​ (4,652,030) ​ ​ ​ ​ ​ 182,351 ​ ​ ​ ​ ​ 644,655 ​ ​ ​ ​ ​ 3,570,229 ​ ​ ​ ​ ​ 5,496,116 ​ ​
2021 ​ ​ ​ ​ 5,217,889 ​ ​ ​ ​ ​ (4,302,448) ​ ​ ​ ​ ​ (213,819) ​ ​ ​ ​ ​ (837,071) ​ ​ ​ ​ ​ 1,983,246 ​ ​ ​ ​ ​ 1,847,797 ​ ​
2020 ​ ​ ​ ​ 3,725,684 ​ ​ ​ ​ ​ (2,791,502) ​ ​ ​ ​ ​ 218,828 ​ ​ ​ ​ ​ 534,106 ​ ​ ​ ​ ​ 2,061,829 ​ ​ ​ ​ ​ 3,748,945 ​ ​
​
(6)
Total Shareholder Return is calculated as the sum of the difference between our share price at the end of each year shown and the beginning of the measurement period plus the cumulative amount of dividends for the investment period, assuming dividend reinvestment, divided by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.
​
(7)
The peer group used for calculating Peer Group Total Shareholder Return is the Nasdaq Biotechnology Index, which is used for determining performance of the relative total shareholder return component for the performance shares awards to the NEOs.
​
(8)
Represents total product revenues, net, as disclosed in the Consolidated Statements of Operations in our Annual Reports on Form 10-K for the years ended December 31, 2024, 2023, 2022, 2021, and 2020.
       
Company Selected Measure Name Total Product Revenues        
Named Executive Officers, Footnote
(1)
The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for Hervé Hoppenot, our CEO.
(4)
Our non-PEO Named Executive Officers for 2024 comprises of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2023 are comprised of Ms. Stamoulis, Dr. Cagnoni, Dr. Stein, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2021 and 2022 were comprised of Ms. Stamoulis, Dr. Stein, Ms. Maria E. Pasquale, and Dr. Flannelly. Our non-PEO Named Executive Officers for 2020 were comprised of Ms. Stamoulis, Dr. Stein, Dr. Flannelly, and Dr. Vijay Iyengar.
       
Peer Group Issuers, Footnote
(7)
The peer group used for calculating Peer Group Total Shareholder Return is the Nasdaq Biotechnology Index, which is used for determining performance of the relative total shareholder return component for the performance shares awards to the NEOs.
       
PEO Total Compensation Amount $ 17,459,546 $ 16,659,526 $ 16,669,368 $ 14,444,265 $ 16,378,192
PEO Actually Paid Compensation Amount $ 25,233,510 7,842,731 15,972,264 6,228,229 13,448,394
Adjustment To PEO Compensation, Footnote
(3)
The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the “Compensation Actually Paid” for our PEO for each of the years presented:
​
Year
​ ​
Reported
Summary
Compensation
Table Total
for PEO
($)
​ ​
Reported
Value of
Equity Awards
($)
​ ​
CAP of
Equity
Vesting
during FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted prior to
the current FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted during
the current FY
($)
​ ​
Compensation
Actually Paid
to PEO
($)
​
2024 ​ ​ ​ ​ 17,459,546 ​ ​ ​ ​ ​ (13,858,712) ​ ​ ​ ​ ​ 304,971 ​ ​ ​ ​ ​ 3,302,113 ​ ​ ​ ​ ​ 18,025,592 ​ ​ ​ ​ ​ 25,233,510 ​ ​
2023 ​ ​ ​ ​ 16,659,526 ​ ​ ​ ​ ​ (13,759,707) ​ ​ ​ ​ ​ (2,202,340) ​ ​ ​ ​ ​ (1,080,176) ​ ​ ​ ​ ​ 8,225,428 ​ ​ ​ ​ ​ 7,842,731 ​ ​
2022 ​ ​ ​ ​ 16,669,368 ​ ​ ​ ​ ​ (13,783,149) ​ ​ ​ ​ ​ 1,005,994 ​ ​ ​ ​ ​ 2,981,288 ​ ​ ​ ​ ​ 9,098,763 ​ ​ ​ ​ ​ 15,972,264 ​ ​
2021 ​ ​ ​ ​ 14,444,265 ​ ​ ​ ​ ​ (12,088,636) ​ ​ ​ ​ ​ (606,066) ​ ​ ​ ​ ​ (1,960,844) ​ ​ ​ ​ ​ 6,439,510 ​ ​ ​ ​ ​ 6,228,229 ​ ​
2020 ​ ​ ​ ​ 16,378,192 ​ ​ ​ ​ ​ (13,832,247) ​ ​ ​ ​ ​ 2,043,085 ​ ​ ​ ​ ​ 127,113 ​ ​ ​ ​ ​ 8,732,251 ​ ​ ​ ​ ​ 13,448,394 ​ ​
       
Non-PEO NEO Average Total Compensation Amount $ 5,906,668 7,843,705 5,750,911 5,217,889 3,725,684
Non-PEO NEO Average Compensation Actually Paid Amount $ 8,882,222 6,405,428 5,496,116 1,847,797 3,748,945
Adjustment to Non-PEO NEO Compensation Footnote
(5)
The following table sets forth the adjustments made to the information provided in the Summary Compensation Table to arrive at the Average Compensation Actually Paid for our non-PEO Named Executive Officers for each of the years presented:
Year
​ ​
Reported
Summary
Compensation
Table Total
for Non-PEO
NEOs
($)
​ ​
Reported
Value of
Equity Awards
($)
​ ​
CAP of
Equity Vesting
during FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted prior to
the current FY
($)
​ ​
CAP of
Unvested
Equity at FYE
granted during
the current FY
($)
​ ​
Compensation
Actually Paid
to Non-PEO
NEOs
($)
​
2024 ​ ​ ​ ​ 5,906,668 ​ ​ ​ ​ ​ (4,361,467) ​ ​ ​ ​ ​ 128,814 ​ ​ ​ ​ ​ 1,514,304 ​ ​ ​ ​ ​ 5,693,903 ​ ​ ​ ​ ​ 8,882,222 ​ ​
2023 ​ ​ ​ ​ 7,843,705 ​ ​ ​ ​ ​ (6,458,845) ​ ​ ​ ​ ​ (291,967) ​ ​ ​ ​ ​ 203,007 ​ ​ ​ ​ ​ 5,109,528 ​ ​ ​ ​ ​ 6,405,428 ​ ​
2022 ​ ​ ​ ​ 5,750,911 ​ ​ ​ ​ ​ (4,652,030) ​ ​ ​ ​ ​ 182,351 ​ ​ ​ ​ ​ 644,655 ​ ​ ​ ​ ​ 3,570,229 ​ ​ ​ ​ ​ 5,496,116 ​ ​
2021 ​ ​ ​ ​ 5,217,889 ​ ​ ​ ​ ​ (4,302,448) ​ ​ ​ ​ ​ (213,819) ​ ​ ​ ​ ​ (837,071) ​ ​ ​ ​ ​ 1,983,246 ​ ​ ​ ​ ​ 1,847,797 ​ ​
2020 ​ ​ ​ ​ 3,725,684 ​ ​ ​ ​ ​ (2,791,502) ​ ​ ​ ​ ​ 218,828 ​ ​ ​ ​ ​ 534,106 ​ ​ ​ ​ ​ 2,061,829 ​ ​ ​ ​ ​ 3,748,945 ​ ​
       
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid Versus Total Shareholder Return 2020-2024
[MISSING IMAGE: bc_tsr-4c.jpg]
TSR is based on the Nasdaq Biotechnology Index, which is the peer group used for the relative TSR component of our Performance Shares awarded to our CEO and other NEOs. It is also the peer group used in the Stock Price
Performance Graph furnished with our Annual Report that is delivered to our stockholders together with this Proxy Statement in connection with our Annual Meeting of Stockholders. Compensation Actually Paid is highly correlated with TSR, given that the values of the components of our executive equity compensation (stock options, restricted stock units and a portion of our performance share goals), depend on our stock price performance.
       
Compensation Actually Paid vs. Net Income
Compensation Actually Paid Versus Net Income (Loss) 2020-2024
[MISSING IMAGE: bc_netincome-4c.jpg]
Incyte does not currently utilize GAAP net income (loss) as a metric in its incentive programs, given that it may include certain one-time/non-recurring items that could make it not reflective of the underlying performance of our business.
       
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid Versus Total Products Revenues, 2020-2024
[MISSING IMAGE: bc_revenue-4c.jpg]
As previously discussed, our CEO and other NEOs’ Compensation Actually Paid is highly dependent on the absolute and relative stock price performance due to the significant portion of our compensation program linked to equity incentives. In addition, other metrics such as total product revenues (which account for a significant portion (40%) of the performance goals for our performance share (PSU) component of our executive officers’ equity compensation in 2021, 2022, and 2023), pipeline progression and regulatory approvals, are also important performance measures that we use to link our performance to compensation actually paid to our executive officers.
       
Total Shareholder Return Vs Peer Group
Compensation Actually Paid Versus Total Shareholder Return 2020-2024
[MISSING IMAGE: bc_tsr-4c.jpg]
TSR is based on the Nasdaq Biotechnology Index, which is the peer group used for the relative TSR component of our Performance Shares awarded to our CEO and other NEOs. It is also the peer group used in the Stock Price
Performance Graph furnished with our Annual Report that is delivered to our stockholders together with this Proxy Statement in connection with our Annual Meeting of Stockholders. Compensation Actually Paid is highly correlated with TSR, given that the values of the components of our executive equity compensation (stock options, restricted stock units and a portion of our performance share goals), depend on our stock price performance.
       
Tabular List, Table
Financial Performance Measures
The following table lists the most important performance measures that we used to link our performance to compensation actually paid to our named executive officers for the most recently completed fiscal year:
Most Important Performance Measures
​
Total product revenues ​
Pipeline development and progression ​
Total shareholder return (TSR) ​
       
Total Shareholder Return Amount $ 79.1 71.91 91.98 84.06 99.61
Peer Group Total Shareholder Return Amount 113.84 115.42 113.65 126.45 126.42
Net Income (Loss) $ 32,600,000 $ 597,600,000 $ 340,700,000 $ 948,600,000 $ (295,700,000)
Company Selected Measure Amount 3,618,900,000 3,165,200,000 2,746,900,000 2,322,000,000 2,068,700,000
PEO Name Hervé Hoppenot        
Measure:: 1          
Pay vs Performance Disclosure          
Name Total product revenues        
Non-GAAP Measure Description
(8)
Represents total product revenues, net, as disclosed in the Consolidated Statements of Operations in our Annual Reports on Form 10-K for the years ended December 31, 2024, 2023, 2022, 2021, and 2020.
       
Measure:: 2          
Pay vs Performance Disclosure          
Name Pipeline development and progression        
Measure:: 3          
Pay vs Performance Disclosure          
Name Total shareholder return (TSR)        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (13,858,712) $ (13,759,707) $ (13,783,149) $ (12,088,636) $ (13,832,247)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 18,025,592 8,225,428 9,098,763 6,439,510 8,732,251
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,302,113 (1,080,176) 2,981,288 (1,960,844) 127,113
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 304,971 (2,202,340) 1,005,994 (606,066) 2,043,085
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (4,361,467) (6,458,845) (4,652,030) (4,302,448) (2,791,502)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 5,693,903 5,109,528 3,570,229 1,983,246 2,061,829
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,514,304 203,007 644,655 (837,071) 534,106
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 128,814 $ (291,967) $ 182,351 $ (213,819) $ 218,828